Advertisement
Akorn Ofloxacin Ophthalmic Solution Recall: A Comprehensive Overview
Author: Dr. Anya Sharma, PharmD, BCPS – A board-certified pharmacotherapist with over 10 years of experience in pharmaceutical safety and recall analysis. Dr. Sharma has published extensively on drug safety and regulatory affairs.
Publisher: The National Institute for Pharmaceutical Research and Development (NIPRD) – A leading research institute dedicated to advancing pharmaceutical sciences and public health.
Editor: Dr. David Lee, PhD, MBA – A seasoned editor with expertise in medical writing and communication, specializing in pharmaceutical safety and regulatory compliance.
Keyword: akorn ofloxacin ophthalmic solution recall
Introduction: Understanding the Akorn Ofloxacin Ophthalmic Solution Recall
The akorn ofloxacin ophthalmic solution recall represents a significant event in pharmaceutical safety. This comprehensive overview delves into the details of the recall, exploring its causes, consequences, and the broader implications for pharmaceutical manufacturing and regulatory oversight. We will examine the scope of the recall, the affected products, and the steps taken by Akorn and regulatory agencies to mitigate potential harm to patients. Understanding this recall is crucial for healthcare professionals, patients, and anyone interested in pharmaceutical safety.
The Scope of the Akorn Ofloxacin Ophthalmic Solution Recall
The akorn ofloxacin ophthalmic solution recall involved multiple batches of ofloxacin ophthalmic solution produced by Akorn, Inc. The recall wasn't limited to a single batch number but affected a wide range of products distributed across various regions. This widespread nature underscores the seriousness of the issues identified during the investigation. The specific batch numbers recalled were publicly announced by the FDA and Akorn, readily available online through the FDA's MedWatch reporting system and Akorn's official website. It's crucial to check those lists if you suspect you might have been affected by the akorn ofloxacin ophthalmic solution recall.
Reasons Behind the Recall: Substandard Quality and Potential Contamination
The primary reason behind the akorn ofloxacin ophthalmic solution recall stemmed from concerns regarding the manufacturing process and potential contamination. Investigations revealed that the products did not meet the required quality standards, leading to concerns about their sterility and potency. This is a critical issue, as ophthalmic solutions are applied directly to the eye, a delicate and vulnerable organ. Any compromise in sterility could lead to serious infections, and variations in potency could render the medication ineffective. The specific details of the contamination, if identified, were made public through official press releases and FDA advisories related to the akorn ofloxacin ophthalmic solution recall.
Impact of the Recall: Patient Safety and Public Health
The akorn ofloxacin ophthalmic solution recall had significant implications for patient safety and public health. Individuals who used the recalled products faced the risk of developing serious eye infections, ranging from mild discomfort to potentially vision-threatening conditions. The FDA actively urged patients to immediately discontinue use of the affected batches and seek medical attention if they experienced any adverse effects. The recall also highlights the broader systemic challenges in pharmaceutical manufacturing, emphasizing the need for stringent quality control measures to prevent future occurrences. The negative impact extended to Akorn's reputation and potentially affected patient trust in the company and generic medications in general.
Regulatory Response and Subsequent Actions
Following the discovery of quality control issues, regulatory agencies, primarily the Food and Drug Administration (FDA), took swift action. They initiated a thorough investigation into Akorn's manufacturing practices and issued a formal recall notification. The FDA collaborated with Akorn to ensure that the recalled products were removed from the market effectively. The agency also enforced stricter regulatory oversight to prevent similar incidents in the future. The akorn ofloxacin ophthalmic solution recall served as a significant case study highlighting the importance of regulatory vigilance in ensuring the safety and efficacy of pharmaceuticals.
Akorn's Response and Steps Taken to Address the Issue
Akorn, Inc., responded to the akorn ofloxacin ophthalmic solution recall by immediately initiating a voluntary recall of the affected products. They cooperated fully with the FDA's investigation and implemented corrective actions aimed at improving their manufacturing processes and quality control measures. Akorn publicly acknowledged the recall, provided detailed information to healthcare professionals and patients, and established communication channels to address concerns and answer questions. Their response aimed to minimize the impact of the recall and rebuild public trust, which is critical for any pharmaceutical company after such an incident.
Long-Term Implications and Lessons Learned
The akorn ofloxacin ophthalmic solution recall served as a cautionary tale, highlighting the critical need for robust quality control systems in pharmaceutical manufacturing. It underscored the importance of continuous monitoring, rigorous testing, and proactive measures to identify and prevent potential safety issues before they reach the market. The experience led to increased scrutiny of pharmaceutical manufacturing practices and reinforced the critical role of regulatory agencies in protecting public health. The long-term implications involved heightened vigilance within the pharmaceutical industry, leading to improvements in manufacturing processes and quality control standards.
Conclusion
The akorn ofloxacin ophthalmic solution recall stands as a significant event in pharmaceutical history, underscoring the importance of rigorous quality control and effective regulatory oversight. The recall’s impact extended beyond the immediate patient safety concerns, serving as a catalyst for industry-wide improvements in manufacturing processes and quality assurance. The lessons learned from this recall are invaluable in ensuring the safety and efficacy of medications for years to come.
FAQs
1. What are the symptoms of an eye infection caused by contaminated ofloxacin ophthalmic solution? Symptoms can range from mild irritation and redness to severe pain, discharge, blurred vision, and even vision loss. Seek immediate medical attention if you experience any eye discomfort after using ofloxacin.
2. How can I determine if my ofloxacin ophthalmic solution is part of the recalled batch? Check the FDA website and Akorn's official website for the complete list of recalled batch numbers. Compare these numbers to the batch number printed on your product packaging.
3. What should I do if I have a recalled bottle of ofloxacin? Immediately discontinue use and contact your pharmacist or healthcare provider for guidance on disposal.
4. Is there a replacement medication available? Your doctor can prescribe an alternative ophthalmic solution if needed.
5. What actions did Akorn take to rectify the situation? Akorn initiated a voluntary recall, cooperated fully with the FDA investigation, and implemented corrective actions to improve manufacturing processes.
6. How can I report an adverse event related to the recalled product? Report any adverse events to the FDA's MedWatch reporting system.
7. What are the long-term consequences for Akorn following this recall? The recall likely impacted Akorn's reputation and might have resulted in financial repercussions and stricter regulatory scrutiny.
8. What changes have been implemented in the pharmaceutical industry as a result of this recall? The recall highlighted the need for stronger quality control measures, improved manufacturing practices, and heightened regulatory oversight within the industry.
9. Where can I find more information on this specific recall? The FDA website, Akorn's website, and reputable medical news sources offer comprehensive information regarding the akorn ofloxacin ophthalmic solution recall.
Related Articles:
1. "Akorn Recall: A Case Study in Pharmaceutical Quality Control Failures": A detailed analysis of the root causes of the recall and Akorn's manufacturing processes.
2. "Patient Safety and the Akorn Ofloxacin Recall: A Public Health Perspective": Focuses on the impact on patients and the public health response.
3. "The FDA's Response to the Akorn Ofloxacin Recall: Strengthening Regulatory Oversight": Examines the FDA's role and subsequent regulatory changes.
4. "Legal Implications of the Akorn Ofloxacin Recall: Product Liability and Consumer Rights": Explores the legal ramifications for Akorn and consumers.
5. "Generic Drug Safety Concerns in the Wake of the Akorn Recall": Discusses the broader implications for the generic drug market.
6. "Improving Pharmaceutical Manufacturing Practices: Lessons Learned from the Akorn Ofloxacin Recall": Focuses on implementing better manufacturing practices.
7. "The Role of Quality Control Laboratories in Preventing Future Recalls: A Look at the Akorn Case": Highlights the importance of quality control testing.
8. "Consumer Advocacy and the Akorn Ofloxacin Recall: Protecting Patient Rights": Examines the role of consumer advocacy groups.
9. "Transparency and Communication in Pharmaceutical Recalls: The Akorn Example": Discusses the importance of clear and timely communication during a recall.
| akorn ofloxacin ophthalmic solution recall: Clinical Ocular Pharmacology Jimmy D. Bartlett, Siret D. Jaanus, 1995 Written by experts in the field, this comprehensive resource offers valuable information on the practical uses of drugs in primary eye care. Discussions of the pharmacology of ocular drugs such as anti-infective agents, anti-glaucoma drugs, and anti-allergy drugs lead to more in-depth information on ocular drugs used to treat a variety of disorders, including diseases of the eyelids, corneal diseases, ocular infections, and glaucoma. The book also covers ocular toxicology, focusing on drug interactions, ocular effects of systemic drugs, and life-threatening systemic emergencies. |
| akorn ofloxacin ophthalmic solution recall: Plumb's Veterinary Drug Handbook Donald C. Plumb, 2018-02-21 Plumb’s Veterinary Drug Handbook, Ninth Edition updates the most complete, detailed, and trusted source of drug information relevant to veterinary medicine. Provides a fully updated edition of the classic veterinary drug handbook, with carefully curated dosages per indication for clear guidance on selecting a dose Features 16 new drugs Offers an authoritative, complete reference for detailed information about animal medication Designed to be used every day in the fast-paced veterinary setting Includes dosages for a wide range of species, including dogs, cats, exotic animals, and farm animals |
| akorn ofloxacin ophthalmic solution recall: Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (Us Food and Drug Administration Regulation) (Fda) (2018 Edition) The Law The Law Library, 2018-09-23 Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (US Food and Drug Administration Regulation) (FDA) (2018 Edition) The Law Library presents the complete text of the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (US Food and Drug Administration Regulation) (FDA) (2018 Edition). Updated as of May 29, 2018 To minimize the risk of serious adverse health consequences or death from consumption of contaminated produce, the Food and Drug Administration (FDA or we) is establishing science-based minimum standards for the safe growing, harvesting, packing, and holding of produce, meaning fruits and vegetables grown for human consumption. FDA is establishing these standards as part of our implementation of the FDA Food Safety and Modernization Act. These standards do not apply to produce that is rarely consumed raw, produce for personal or on-farm consumption, or produce that is not a raw agricultural commodity. In addition, produce that receives commercial processing that adequately reduces the presence of microorganisms of public health significance is eligible for exemption from the requirements of this rule. The rule sets forth procedures, processes, and practices that minimize the risk of serious adverse health consequences or death, including those reasonably necessary to prevent the introduction of known or reasonably foreseeable biological hazards into or onto produce and to provide reasonable assurances that the produce is not adulterated on account of such hazards. We expect the rule to reduce foodborne illness associated with the consumption of contaminated produce. This book contains: - The complete text of the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (US Food and Drug Administration Regulation) (FDA) (2018 Edition) - A table of contents with the page number of each section |
| akorn ofloxacin ophthalmic solution recall: Ophthalmology Explorer Dhaval Patel, 2014-01-07 This is ophthalmology PG Exam preparation manual I have prepared during my residency and added up while preparing for senior residency/ fellowship examinations which may serve as a small guide to your exams. It will also serve as a good collection of facts which we might forget/neglect during overall MD/MS exam preparation. |
| akorn ofloxacin ophthalmic solution recall: Ophthalmic Product Development Seshadri Neervannan, Uday B. Kompella, 2022-03-11 This is a comprehensive textbook addressing the unique aspects of drug development for ophthalmic use. Beginning with a perspective on anatomy and physiology of the eye, the book provides a critical appraisal of principles that underlie ocular drug product development. The coverage encompasses topical and intraocular formulations, small molecules and biologics (including protein and gene therapies), conventional formulations (including solutions, suspensions, and emulsions), novel formulations (including nanoparticles, microparticles, and hydrogels), devices, and specialty products. Critical elements such as pharmacokinetics, influence of formulation technologies and ingredients, as well as impact of disease conditions on products development are addressed. Products intended for both the front and the back of the eye are discussed with an eye towards future advances. @font-face {font-family:Cambria Math; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1073732485 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:Times New Roman,serif; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-ansi-language:EN-US; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:Calibri,sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:Times New Roman; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} |
| akorn ofloxacin ophthalmic solution recall: The Biology of the Eye Jorge Fischbarg, 2005-12-09 Acknowledgement This book is the result of a collective effort. Due to an oversight, mention of three of the contributors who played an especially decisive role in bringing the work to fruition was omitted from the book. They should share fully in the intellectual credits accruing from this publication. I would therefore like to acknowledge and thank the following for their outstanding contributions to editing the work: Dr. Morten Dornonville la Cour (MD, Dr. Med. Sci.) solicited and edited the chapters on retina, RPE, choroid, vitreous, immunology, and sclera. Dr. la Cour is a Lecturer, Eye Department, Copenhagen University Hospital, specializes in vitreoretinal surgery, and frequently lectures in the international scene. A trained mathematician, he has done research in retinal pigment epithelial physiology in the laboratories of Drs. Thomas Zeuthen and Sheldon Miller. Dr. Friedrich P.J. Diecke and Dr. Elliott M. Kanner also provided invaluable editorial assistance. Dr Diecke, who was formerly Professor and Chairman of the Department of Physiology, UMDNJ-New Jersey Medical School, is a Professor Emeritus at that institution. His research has concentrated on membrane transport mechanisms in lens epithelial cells, corneal endothelial cells and peripheral nerve and on the regulation of vascular smooth muscle contraction. Dr. Elliott M. Kanner was born in Canada in 1970. He graduated from Yale University in 1992 with a BS/MS degree in Molecular Biophysics and Biochemistry. He received his PhD degree from the Rockefeller University in 1999 and his MD degree from Weill/Cornell in 2001. He is currently an Ophthalmology resident at Columbia University. Jorge Fischbarg, December 2005 This book explores the many recent novel ideas about the eye in a systematic and synthetic way. It includes both basic sciences and applications towards clinical research. Chapters include both anatomical and functional descriptions of the different ocular tissues and treatments of a few subjects of practical importance for ophthalmologists. This book is intended for students in basic biomedical science interested in the eye, as well as ophthalmologists a comprehensive source on recent developments in ocular research.* Combines basic science and practical opthalmological subjects * Written with the simplicity of a textbook, while maintaining the comprehensive and rigorous approach of science papers * Includes contributions by well-known experts |
| akorn ofloxacin ophthalmic solution recall: Neuro-ophthalmic Disorders Preeti Patil Chhablani, 2019-10-03 This book discusses in detail the major advances in the field of neuro-ophthalmology. Based on the latest research from across the globe, it highlights recent developments in all areas of neuro-ophthalmology, including optic neuritis and the associated demyelinating diseases – especially the changing paradigms in the diagnosis and management of multiple sclerosis and neuromyelitis optica. It also covers the various types of hereditary optic neuropathies as well as nystagmus and its management. In order to provide comprehensive information in a single volume, it addresses topics of interest in pediatric neuro-ophthalmology, such as pediatric optic neuritis and cortical visual impairment, innovations in the management of ocular motility disorders and other disorders of the optic nerve and central nervous system, including ischemic neuropathies and idiopathic intracranial hypertension.This book provides a one-stop source of information on all key topics of neuro-ophthalmology, enabling trainee fellows and practitioners to keep abreast of the current thoughts in this field.As part of the series “Current Practices in Ophthalmology” this volume is intended for residents and fellows-in-training, as well as generalist and specialist ophthalmologists alike. |
| akorn ofloxacin ophthalmic solution recall: Litt's Drug Eruption & Reaction Manual Neil H. Shear, 2021-01-18 Internationally relied upon by medical practitioners for its unparalleled focus on adverse effects and cutaneous reactions, Litt’s Drug Eruption & Reaction Manual is a succinct clinical reference and essential drug-safety tool for patient care. This 27th edition is a comprehensively revised and updated quick reference, and each entry includes: * Quantitative summaries of reports and incidence for reactions * Drug–drug interactions * Categories of adverse drug reactions, eruptions, and cutaneous reaction patterns * Essential reference information on prescription and over-the-counter drugs as well as herbals and supplements The book contains... * A to Z listing of the 1500 most consulted drug and herbal profiles, including generic name and trade names; pharmaceutical company; indications; half-life; and pregnancy category * Over 31,000 adverse reactions and drug-eruption listings * Includes supplements, vaccines, and botanicals * Clinical definitions of common and severe adverse reactions * List of drugs that cause severe adverse reactions * List of main classes of drugs as a quick clinical reference guide * 27 tables of members of a class of drugs (such as statins or monoclonal antibodies), enabling clinicians to see at a glance whether a reaction is common to all drugs included in that class, or to a majority of them, or is known in only a handful—information that is critical for an informed decision to change drugs within the same class * 2 extensive tables showing reported genetic associations with cutaneous adverse drug reactions and recommendations regarding genetic screening to prevent cutaneous adverse drug reactions * A concordance of synonyms and trade names for ease of cross-reference Markets: Dermatologists, Neurologists, Oncologists, Psychiatrists, Pharmacists, Family Physicians, and those caring for patients on multiple medications, such as Geriatricians and Hospital Generalist Physicians. Litt’s Drug Eruption & Reaction Manual is a succinct clinical reference derived from Litt’s Drug Eruption & Reaction Database, located at www.drugeruptiondata.com, which currently holds over 1750 drug profiles with almost 70,000 documented drug reactions, as evidenced by well over 145,000 references on PubMed. Quick and easy access via the Litt app provides real time access to the most up-to-date drug safety information to a busy practitioner on-the-go. Subscribers to the database benefit from: * Easy access via the Litt app, ideal for working across a number of work-places * Full drug profiles with a wealth of information including category, half-life, indications, drug-drug interactions, and known adverse reactions * Links to PubMed abstracts * Searching a class of drugs for a specific reaction * Searching by adverse reaction pattern * Searching by indication for a drug * Searching by drug name (generic name/brand name) as well as by pharmaceutical company or drug class * Searching herbal medicines and supplements * Diagnosing the cause of reactions in patients on multiple drugs by selecting the adverse reaction(s) experienced and the drug(s) the patient is taking * Comparing reaction profiles for up to four drugs in a customized chart that can be saved for future reference * Descriptions of reaction patterns * Photographs of adverse reactions * Access via a computer, tablet, or smartphone * Regular updates To learn more, and to subscribe to the database, visit www.drugeruptiondata.com. |
| akorn ofloxacin ophthalmic solution recall: Retinal Imaging David Huang, 2006 SECTION I: IMAGING MODALITIES: BASIC PRINCIPLES & INTERPRETATION -- 1. Fluorescein angiography -- 2. Indocyanine green angiography -- 3. Optical coherence tomography (OCT) -- -- 4. Optical coherence tomographic ophthalmoscopy -- 5. Ultrasound -- 6. Scanning laser tomography -- 7. Scanning laser polarimetry -- 8. Retinal thickness analyzer -- 9. Adaptive optics ophthalmoscopy -- 10. Imaging of Ocular Blood Flow -- SECTION II: MACULAR DISEASES -- 11. Non-neovascular age-related macular degeneration -- -- 12. Neovascular Age-Related Macular Degeneration -- 13. Pathologic myopia -- 14. Central serous retinopathy -- 15. Macular holes -- 16. Epiretinal membranes -- 17. Macular dystrophies -- 18. Cystoid macular edema -- 19. Angiod streaks -- 20. Chrorioretinal folds -- SECTION III: RETINAL VASCULAR DISEASES -- 21. Diabetic Retinopathy -- 22. Arterial obstructive disease -- 23. Venous obstructive disease -- 24. Parafoveal Telangiectasis -- 25. Coats' disease -- 26. Retinopathy of prematurity -- 27. Ocular ischemic syndrome -- 28. Hypertensive retinopathy -- 29. Radiation retinopathy -- 30. Retinal artery macroanuerysm -- SECTION IV: INFLAMMATORY & INFECTIOUS DISEASES -- 31. Posterior Scleritis -- -- 32. Pars Planitis -- 33. Sarcoidosis -- 34. Uveal Effusion Syndrome -- 35. White Dot Syndromes -- -- 36. Sympathetic Ophthalmia -- 37. Vogt-Koyanagi-Harada Disease -- 38. Syphilis -- 39. Tuberculosis -- 40. Ocular Histoplasmosis -- 41. Fungal Infections -- 42. Endophthalmitis -- 43. Acute Retinal Necrosis -- 44. Toxoplasmosis -- 45. Toxocariasis -- 46. Cysticercosis -- 47. Diffuse Unilateral Subacute Neuroretinitis -- 48. Cytomegalovirus Retinitis -- SECTION V: OTHER RETINAL DISEASES -- 49. Ocular Phototoxicity -- 50. Metabolic and nutritional anomalies -- 51. Medications and Retinal Toxicity -- 52. Retinal injuries -- 53. Hereditary/congenital vitreoretinal disorders -- 54. Retinitis pigmentosa and allied disorders -- SECTION VI: TUMORS -- 55. Retinoblastoma -- 56. Choroidal malignant melanoma -- 57. Choroidal nevus -- 58. Cavernous hemangioma of the retina -- 59. Retinal capillary hemangioma -- 60. Choroidal hemangioma -- -- 61. Tuberous sclerosis complex -- 62. Tumors and related lesions of the retinal pigment epithelium -- 63. Congenital hypertrophy of the retinal pigment epithelium and other pigmented lesions -- 64. Choroidal/retinal metastasis -- 65. Osteomas -- 66. Leukemia /lymphomas -- SECTION VII: OPTIC NERVE DISORDERS -- 67. Optic pits -- 68. Optic nerve head drusen -- 69. Melanocytoma of the optic disc -- 70. Papilledema -- 71. Glaucoma -- 72. Other optic nerve malformations. |
| akorn ofloxacin ophthalmic solution recall: Anterior Segment Complications of Contact Lens Wear Joel A. Silbert, 2000 This comprehensive, full-color text provides clinically useful information on anterior segment complications of contact lens wear and their clinical management. |
| akorn ofloxacin ophthalmic solution recall: Zoo Animal and Wildlife Immobilization and Anesthesia Gary West, Darryl Heard, Nigel Caulkett, 2013-05-13 Zoo Animal and Wildlife Immobilization and Anesthesia is the definitive, comprehensive reference for the growing fields of zoo, wildlife, and exotic animal veterinary medicine. This book covers key aspects of immobilization and anesthesia from pharmacology and restraint to supportive care. Alongside these chapters, the editors have brought together an impressive collection of species-specific chapters that will be an invaluable resource to those called upon to treat these animals. |
| akorn ofloxacin ophthalmic solution recall: Prescribing for Elderly Patients Stephen Jackson, Paul Jansen, Arduino Mangoni, 2009-04-22 A guide for doctors to quickly choose the right drugs in the right dose for the most important clinical problems in the elderly Prescribing medications for elderly patients is complex - this book gives clear advice on treatment regimes, drug interactions, adverse effects, and recommended dose changes Provides practical help with the problems that can arise in reaching an accurate diagnosis in the elderly, recommends clear treatment options, lists key drug interactions and side effects, and advises when to amend doses |
| akorn ofloxacin ophthalmic solution recall: Saunders Handbook of Veterinary Drugs Mark G. Papich, 2007 Accompanying CD-ROM contains ... customizable client information handouts for 125 of the most commonly prescribed small animal drugs, with clear, concise instructions that encourage compliance.--Page 4 of cover. |
| akorn ofloxacin ophthalmic solution recall: Handbook of Wildlife Chemical Immobilization 5th Edition Terry Kreeger, Jon Arnemo, 2018-02-13 2018 5th edition. 472 four-color pages. New reinforced, fold-flat flexbound cover. Price unchanged for over ten years. Drug doses for over 500 species. The Handbook covers legalities of drug possession and use; types of drugs used for animal capture; equipment used for animal capture; animal capture procedures and techniques; animal medical treatment; and human emergency medicine, supported by over 2,750 references. |
| akorn ofloxacin ophthalmic solution recall: Vision and Aging Alfred A. Rosenbloom, Meredith W. Morgan, 1993 Comprehensive text on the relevant clinical concepts and information useful for the effective vision care of the elderly patient. * - authored by well known authorities in the field of low vision and primary care * - strong clinical emphasis * - Comprehensive text on the relevant clinical concepts and information useful for the effective vision care of the elderly patient. |
| akorn ofloxacin ophthalmic solution recall: Exotic Animal Formulary Natalie Antinoff, 1999 This book blends cutting-edge research with actionable guidance to support your leadership journey - whether you're sitting behind the manager's desk or leading from within the team. Utilizing his distinctive storytelling voice, Josh Vaisman guides you through the four pillars of positive leadership: Psychological Safety: creating a safe place for interpersonal risk Purpose: highlighting the Why of the work we do Path: leveraging role clarity and autonomy Partnership: cultivating a sense of inclusion and belonging Lead to Thrive: The Science of Crafting a Positive Veterinary Culture helps you rediscover what you always loved about the veterinary profession, find meaning in the everyday, and learn how to promote wellbeing within your team, one step at a time. |
Akorn Operating Company LLC
In February 2023, Akorn Operating Company LLC filed Chapter 7 bankruptcy. In connection with that filing, the company has ceased and shutdown all operations. Click here to view the …
URGENT Drug Recall Notice Various Human and Animal …
Various Human and Animal Products Within Expiry Manufactured by Akorn Date: 04/26/2023 Dear Valued Customer: , the company has ceased and shutdown all operations and …
Akorn Operating Company LLC
In February 2023, Akorn Operating Company LLC filed Chapter 7 bankruptcy. In connection with that filing, the company has ceased and shutdown all operations. Click here to view the …
URGENT Drug Recall Notice Various Human and Animal …
Various Human and Animal Products Within Expiry Manufactured by Akorn Date: 04/26/2023 Dear Valued Customer: , the company has ceased and shutdown all operations and …
